Gross Margin % is calculated as gross profit divided by its revenue. Ainos's Gross Profit for the
three
months ended in Dec. 2024 was $0.00 Mil. Ainos's Revenue for the
three
months ended in Dec. 2024 was $0.00 Mil. Therefore, Ainos's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%.
If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.
The historical rank and industry rank for Ainos's Gross Margin % or its related term are showing as below:
AIMD'
s Gross Margin % Range Over the Past 10 Years
Min: -208.2 Med: 27.21 Max: 76.1
Current: -152.38
During the past 13 years, the highestGross Margin % of Ainos was 76.10%. The lowest was -208.20%. And the median was 27.21%.
AIMD's Gross Margin % is ranked worse than 98.38% of 802
companies
in the Medical Devices & Instruments industry
Industry Median: 53.055
vs AIMD: -152.38
Ainos had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Ainos was 0.00% per year.
Ainos Gross Margin % Historical Data
The historical data trend for Ainos's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Ainos's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ainos's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ainos's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ainos's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ainos (NAS:AIMD) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ainos had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ainos Gross Margin % Related Terms
Thank you for viewing the detailed overview of Ainos's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AIMD has been successfully added to your 